Sign Up | Log In | What is SocialPicks?

Good Investment Ideas By People You Trust

SocialPicks is a community where stock investors exchange ideas and track performance of financial bloggers.

Are you a stock guru?

Share picks & earn reputation

Mike Havrilla www.ProActiveNewsRoom.com

Start Tracking Mike Havrilla - Add to Friends - Send Message

Community Rank: Principal (7000 pts) | Member since 07/15/2008

Picks Performance:

Outperforms

73%

of community

What's this?

All-time Return +1.04% (in 1 year)	Risk (SD) Conservative 0.00%	Sharpe Ratio -2.09
Followers 68	Winning Picks 786 of 1807	Total Views 906118

Overview

Stocks

Stats

Community

Widget

Last Activity: Added DNDN to bullish list on 11/20/09

Current Stock List:

Symbol	SP Sentiment	Return	Since
DNDN		+0.39%	11/20/09
UNIFF	N/A	n/a	11/19/09
BIO		-0.91%	11/19/09
ECTE	N/A	n/a	11/19/09
ABT		-0.41%	11/19/09
JNJ		+0.18%	11/19/09
CERS		+20.70%	11/17/09
GENZ		-0.72%	11/16/09
CYTX		+14.52%	11/16/09
NFES	N/A	n/a	11/14/09

All-time Sectors of Interest

... View All >

Opinion & Analysis

BioMed News Bytes: CombinatoRx, Dendreon, Photocure.. about DNDN 11/20/09
On 11/2/09, Dendreon (NASDAQ: DNDN) announced that it has completed the submission of its amended Biologics License Application (BLA) for PROVENGE (sipuleucel-T), seeking approval for men with metasta...

BioMed News Bytes: AstraZeneca, Delcath, Unilife about UNIFF 11/19/09
On 11/19/09, AstraZeneca (NYSE: AZN) announced the submission of a New Drug Application (NDA) to the FDA for ticagrelor, an investigational oral antiplatelet treatment for the reduct...

Echo Therapeutics: Positive Developments for Needle.. about BIO 11/19/09
Echo Therapeutics (OTC: ECTE.OB) is a diabetes management company developing the needle-free Symphony Transdermal Continuous Glucose Monitoring (tCGM) System as a non-invasive, wireless, transdermal s...

Echo Therapeutics: Positive Developments for Needle.. about ECTE 11/19/09
Echo Therapeutics (OTC: ECTE.OB) is a diabetes management company developing the needle-free Symphony Transdermal Continuous Glucose Monitoring (tCGM) System as a non-invasive, wireless, transdermal s...

Epinex Diagnostics: A New Paradigm for Diabetic Tes.. about ABT 11/19/09
Epinex Diagnostics Inc. (click on preceding link for the Company's News Room page) is a private company that is dedicated to the development of innovative point-of-care technologies using rapid...

... View All >

Blog Posts

MM ONTY Oncothyreon (ONTY) Research Note 03/18/09 — Visit the BioMedReports.com research section to view or download the PDF for Cougar Biotechnology (CGRB) along with other free PDF reports and corporate investor presentations:http://biomedreports.com/research.htmlOncothyreon (ONTY): Price: $1.21; Market Cap (MM): $23.6Market Outperform; Target Price...

Read 1 comment

MM CGRB Cougar Biotech Research Note 03/17/09 — Visit the BioMedReports.com research section to view or download the PDF for Cougar Biotechnology (CGRB) along with other free PDF reports and corporate investor presentations:http://biomedreports.com/research.htmlCGRB: Price: $28.46; Market Cap (MM): $590.1Market Outperform; Target Price: $36.00Simo...

Read 0 comments

DRRX UTHR Updated Clinical Trial and FDA Calendars 03/17/09 — Below is a summary of updates to the www.BioMedReports.com database of 243 entries included in the FDA and Clinical Trial Calendars.http://biomedreports.com/fda-calendar.html The FDA Calendar includes companies with pending new drug, biological agent, or medical device new product decisions at the FD...

Read 0 comments

MM SNTA Synta Pharma Proceeds with Clinical Trial 03/17/09 — Visit the BioMedReports.com research section to view or download the PDF for Synta Pharma (SNTA) along with other free PDF reports and presentations:http://biomedreports.com/research.htmlSynta Pharma: Price: $1.94; Market Cap (MM): $65.8Market Perform; Simos Simeonidis, Ph.D. - Senior Biotech Analyst...

Read 0 comments

MM PARD Poniard Pharma Awaits Key Cancer Drug Data 03/17/09 — Visit the BioMedReports.com research section to view or download the six page PDF for Poniard Pharma (PARD) along with other free PDF reports and presentations:http://biomedreports.com/research.htmlPARD: Price: $1.87; Market Cap (MM): $64.9Market Outperform; Target Price: $10.00Simos Simeonidis, Ph.D...

Read 0 comments

... View All >

Discussions

Mike Havrilla hasn't participated in any discussions yet.

People Following Mike Havrilla ...

Mathieu Godbout Paquet

Principal

73%

Ahmed El Alfy

Analyst

N/A

blackbirdk01

Analyst

N/A

... View All >

Mike Havrilla is Following ...

Jeremy McDonald

Associate

76%

Greg

Associate

73%

Locationh

Sr. Associate

61%

... View All >

Friends of Mike Havrilla ...

charmed

Analyst

N/A

Ahmed El Alfy

Analyst

N/A

blackbirdk01

Analyst

N/A

... View All >

Similarity to Me ?

Compare Your Portfolio With Mike Havrilla: Enter stocks you like & track your performance:

Symbols, separated by space (e.g. AAPL GOOG MSFT)

More about Mike Havrilla

Investment Style:
Moderate [?]

Avg exp holding time:
84.43 days

Age: 30's	Occupation: Online Media Entrepreneur
Location: USA

Website:
www.ProActiveNewsRoom.com

About Me:

Mike Havrilla is an index developer, pharmacist, writer, and Co-Founder of BioMedReports.com with ex ... more

Similar Portfolios

Marian Filo (supratrade) 62% 55%

Art (unicomtrade.com) N/A 32%

Statistician (optimist) N/A 32%

Steven Halpern (trackstevenhalpern_bloggingstocks) 56% 21%

Zacks.com (zacks.com) 28% 21%

IN THE PRESS

None of the information contained on SocialPicks.com constitutes a recommendation by SocialPicks or its users that any particular security, portfolio of securities, transaction, or investment strategy is suitable for any specific person. SocialPicks is not responsible for the posts, discussions, and recommendations of the users on the Site. SocialPicks does not provide investment advice. You must make your own independent decisions regarding any security, portfolio of securities, transaction, or investment strategy mentioned on the website. SocialPicks' users' past results are not necessarily indicative of future performance. Neither SocialPicks nor any of its users guarantees any specific outcome or profit, and you should be aware of the real risk of loss in following any strategy or investments discussed on the website. You understand and agree that you use the Site and Services at your own discretion and risk and that you will be solely responsible for any damages that arise from such use. Before acting on any information contained on the website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.